Abstract
Vitamin K antagonists, such as warfarin, are the gold standard approach for the long-term anticoagulant therapy of patients with mechanical heart valves. Management decisions are, however, based predominantly on expert consensus and on data from nonrandomized, follow-up studies, which have inherent limitations in their methods. Low-intensity anticoagulation therapy provides protection against thromboembolic complications in patients with most types of modern prosthetic heart valve. The addition of low-dose aspirin is safe if international normalized ratio values below 3.5 are maintained. A combined regimen should be considered in high-risk patients and those with coexistent coronary artery or cerebrovascular disease, and in patients who have suffered a thromboembolic event despite a therapeutic international normalized ratio. Thromboprophylaxis with unfractionated or low-molecular-weight heparins is restricted to specific situations, such as when a patient is intolerant to vitamin K antagonists, when surgical procedures require discontinuation of oral anticoagulation, or when the patient is pregnant. A lack of uniformity across practice guidelines make it difficult to reach treatment decisions. Each patient's preference, expressed after counseling about the risks and benefits of each treatment strategy, and an individual assessment of the patient's risk factors, should guide treatment decisions. At present, new anticoagulant agents such as factor Xa inhibitors do not represent a treatment option for heart valve recipients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ansell J et al. (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S204–S233; erratum Chest 127: 415–416
Salem DN et al. (2004) Antithrombotic therapy in valvular heart disease—native and prosthetic. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S457–S482
Cannegieter SC et al. (1994) Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89: 635–641
Grunkemeier GL and Wu YX (2003) “Our complication rates are lower than theirs”: statistical critique of heart valve comparisons. J Thorac Cardiovasc Surg 125: 290–300
Devereaux PJ et al. (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 323: 1218–1222
Bodnar E (1992) A critical assessment of thrombosis and embolism reporting methods. In Thrombosis, embolism and bleeding, 476–484 (Eds Butchart EG and Bodnar E) ICR Publishers: London
Horstkotte D et al. (1993) Unexpected findings concerning thromboembolic complications and anticoagulation after complete ten year follow up of patients with St. Jude Medical Prostheses. J Heart Valve Dis 2: 291–301
Horstkotte D et al. (1994) Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 107: 1136–1145
Horstkotte D (1996) Results with mechanical cardiac valvular prostheses. Ann Thorac Surg 62: 1565–1567
Horstkotte D (2003) Problems with complication rate analysis. J Thorac Cardiovasc Surg 126: 1668–1670
Bodnar E and Horstkotte D (1993) Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 2: 287–290
Horstkotte D et al. (2005) Recommendations for reporting morbid events after heart valve surgery. J Heart Valve Dis 14: 1–7
Horstkotte D et al. (1993) German Experience with Low Intensity Anticoagulation (GELIA): protocol of a multi-center randomized, prospective study with the St. Jude Medical valve. J Heart Valve Dis 2: 411–419
Hering D et al. (2005) Thromboembolic and bleeding complications following St. Jude Medical valve replacement: Results from the German Experience with Low Intensity Anticoagulation study. Chest 127: 53–59
Piper C and Horstkotte D (2004) State of the art anticoagulation management. J Heart Valve Dis 13 (Suppl 1): S76–S80
van Nooten GJ et al. (2003) Lower-intensity anticoagulation for mechanical heart valves: a new concept with the ATS bileaflet aortic valve. J Heart Valve Dis 12: 495–502
van den Besselaar AM (1996) Precision and accuracy of the international normalized ratio in oral anticoagulant control. Haemostasis 26 (Suppl 4): S248–S265
Loeliger EA (1992) Therapeutic target values in oral anticoagulation: justification of Dutch policy and a warning against so-called moderate-intensity regimens. Ann Hematol 64: 60–65
Chesebro JH et al. (1986) Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 8 (Suppl B): S41B–S56B
Stein PD and Kantrowitz A (1989) Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 95 (Suppl): S107–S117
Saour JH et al. (1990) Trials of different intensities of anticoagulation in patients with prosthetic valves. N Engl J Med 322: 428–432
Altman R et al. (1991) Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 101: 427–431
Wilson DB et al. (1991) Low-intensity anticoagulation in mechanical cardiac prosthetic valves. Chest 100: 1553–1557
Acar J et al. (1996) AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 94: 2107–2112
Meschengieser SS et al. (1997) Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 113: 910–916
Bonow RO et al. (1998) ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). J Am Coll Cardiol 32: 1468–1588
Horstkotte D (1992) Abnormal cardiac anatomy and physiology. In Thrombosis, embolism and bleeding, 31–69 (Eds Butchart EG and Bodnar E) ICR Publishers: London
Schrör K (2001) Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement. Eur Heart J 3 (Suppl Q): S54Q–S59Q
Cappelleri JC et al. (1995) Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart valve replacement: a meta-analysis. Am Heart J 130: 547–552
Hurlen M et al. (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347: 969–974
van Es RF et al. (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360: 109–113
Völler H et al. (2001) Home management of anticoagulation. Eur Heart J 3 (Suppl Q): S44Q–S49Q
Horstkotte D and Piper C (2004) Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis 13: 335–338
Jafri SM (2004) Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J 147: 3–15
Gohlke-Bärwolf C et al. (1995) Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 16: 1320–1330
Kearon C and Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336: 1506–1511
Gohlke-Bärwolf C (2000) Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. Heart 84: 567–572
Shapira Y et al. (2001) Anticoagulant management of patients with mechanical prosthetic valves undergoing non-cardiac surgery: indications and unresolved issues. J Heart Valve Dis 10: 380–387
Tinker JH and Tarhan S (1978) Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 239: 738–739
Katholi RE et al. (1976) Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 92: 162–167
Katholi RE et al. (1978) The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J 96: 163–165
Ananthasubramaniam K et al. (2001) How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 119: 478–484
Aguilar D and Goldhaber SZ (1999) Clinical uses of low-molecular-weight heparins. Chest 115: 1418–1423
Hirsh J and Raschke R (2004) Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S188–S203
Hering D and Horstkotte D (2003) Role of low-molecular-weight heparins for the anticoagulant treatment of patients with prosthetic heart valves. Dtsch Med Wochenschr 128: 1129–1133
Frydman A (1996) Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 26 (Suppl 2): S24–S38
Samama MM and Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 26 (Suppl 1): S31–S38
Montalescot G et al. (2000) Low molecular weight heparin after mechanical heart valve replacement. Circulation 101: 1083–1086
Ginsberg JS et al. (2003) Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 163: 694–698
Bates SM et al. (2004) Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S627–S644
Chan WS et al. (2000) Anticoagulation of pregnant women with mechanical heart valves. A systematic review of the literature. Arch Intern Med 160: 191–196
Vitale N et al. (1999) Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 33: 1637–1641
Weitz JI et al. (2004) New anticoagulant drugs. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): S265–S286
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- INTERNATIONAL NORMALIZED RATIO (INR)
-
A method that standardizes prothrombin times obtained from reagents of different sensitivities, allowing for comparison between different laboratories
- ANTI-XA TEST
-
Assay used to assess coagulation activity when low-molecular-weight heparins are used, the anticoagulant effect of which is achieved predominantly or exclusively by inhibition of coagulation factor Xa
Rights and permissions
About this article
Cite this article
Hering, D., Piper, C. & Horstkotte, D. Drug Insight: an overview of current anticoagulation therapy after heart valve replacement. Nat Rev Cardiol 2, 415–422 (2005). https://doi.org/10.1038/ncpcardio0271
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0271